This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary CAR Therapy Disease Target Discovery
CAR-T cells achieve targeted destruction of tumor cells by specifically recognizing antigens on their surfaces. Thus, the choice of target antigens is crucial in CAR-T research. Although several human CAR T therapies have received approval, introducing these therapies into veterinary medicine presents numerous challenges. Species-specific differences lead to distinct interactions between CAR-T cells and tumor targets in animal models. Consequently, it is essential to develop disease targets for CAR therapies that are specific to particular animal species. BioVenic's Veterinary CAR Therapy Disease Target Discovery platform addresses the needs of various animal types, organs, tissues, and disease categories by integrating gene testing, mRNA expression analysis, and high-throughput detection for proteins and metabolites. Our comprehensive services assist researchers in identifying and assessing animal disease targets, facilitating the advancement of veterinary CAR-related cell therapies.
Fig.1. Overall Scheme for CAR Therapy in Veterinary Medicine.1,2
Veterinary CAR Therapy Disease Target Discovery Services
To improve the effectiveness of CAR cell therapies, it is crucial to identify and validate targets that are specifically overexpressed in abnormal cells like cancer cells, while being minimally expressed in normal cells. Our Veterinary CAR Therapy Disease Target Discovery services offer comprehensive evaluation of potential targets, focusing on both gene and protein expression levels. Utilizing our omics research platform, researchers can perform high-throughput screening of targets across numerous samples, thereby facilitating the development of novel targets for veterinary CAR therapies.
- High-throughput Sequencing Service
High-throughput sequencing platforms have demonstrated immense potential in tumor screening and diagnosis, efficacy prediction, recurrence, metastasis, and prognosis. NGS-based genetic testing has been widely used to guide precision targeted therapy for diseased animals. Our high-throughput sequencing platform can provide high-throughput sequencing and data analysis services for various animal and cell samples, aimed at guiding the development of subsequent veterinary targeted cell therapies. By conducting genome analysis, transcriptome analysis, mutation detection, epigenome analysis, and a series of other high-throughput sequencing and analyses on disease samples and normal samples, scientists can identify potential targets specific to certain veterinary diseases.
- High-throughput Proteomics Detection Service
Currently, the vast majority of drug treatment targets are proteins. The rapid advancement of proteomics technology has enabled the mapping of a large number of tumor proteome molecular profiles, showcasing the immense potential of proteomics in the development of precision therapies for veterinary oncology. Protein antigens related to diseases such as tumors have extensive research value. BioVenic's proteomics detection service can assist researchers in investigating proteins that are overexpressed in animal tumor samples but have restricted expression in normal tissues. These antigenic proteins may become candidate targets for veterinary cell therapy. Our proteomics detection platform features high throughput and high resolution, and it can support various subsequent data analyses to aid researchers in exploring and screening potential protein targets for veterinary CAR therapies.
- Integrated Veterinary Disease Target Function Validation Service
The advent of next-generation rapid and reliable genomics and proteomics detection technologies for biological samples has contributed to identifying a plethora of targets potentially applicable to cancer treatment. However, translating potential targets into pharmacological candidates requires a thorough understanding of the molecular basis of cellular processes. Our veterinary disease target function validation service provides a variety of in vivo and in vitro models that enable comprehensive and in-depth studies of the potential target proteins of interest. Leveraging our gene editing service, we can perform operations such as knockdown and overexpression on specific target genes within animal cell lines, thus exploring the functions of these potential targets. By integrating various biochemical assays, immunological assays, and high-throughput omics techniques, our veterinary disease target function validation service facilitates the characterization and study of animal tumor targets, aiding in the subsequent CAR design and development of veterinary CAR-related cell therapies.
Table. 1 Determinant of Target Selection for CAR-T Therapy3
| Determinant | Main Effect | Selection Criteria |
| Coverage | Tumor clearance efficiency |
1. It should be high enough, and it is possible to obtain CRR response using antibodies or CAR-T therapy against this target. 2. Refer to the efficacy of related antibody drugs. 3. Test patients' samples before the treatment. |
| Specificity | "Off-tumor" cytotoxicity |
1. It is limited to tumor tissue, or the damage caused by off-tumor toxicity can be tolerated or well managed. 2. Refer to the side effect of related antibody drugs. |
| Stability | Response duration and recurrence |
1. The expression should be stable and not easily regulated by external signals. 2. It plays an important role in the growth and survival of cancer cells. |
Why Choose Us?
Focused on Animals
Our researchers are well aware of the potential differences in tumor targets between companion animals, laboratory animals, and humans. We offer customized solutions tailored to different animal types.
Multiple Detection Services
Our high-throughput sequencing and protein detection services provide valuable data for the screening of target proteins, aiding the development of veterinary CAR-related cell therapies.
Integrated Service Resources
With our in vivo and in vitro research platforms, researchers can characterize and explore the function of potential veterinary disease targets. Our one-stop solution helps reduce various issues researchers face in target validation.
The discovery of disease targets is one of the initial steps in the development of veterinary CAR-related cell therapies. With BioVenic's diverse services for testing animal samples, researchers can explore differential targets between disease samples and normal samples. Our protein characterization service, biochemical testing service, and immunological testing service combined with our in vivo and in vitro models can provide researchers with structural and functional characteristics of potential targets, serving as a reference for subsequent CAR design and the development of veterinary CAR cell therapies. If you are interested in our veterinary CAR therapy disease target discovery services, please feel free to contact us for further communication.
Reference
- Image retrieved from Figure 1 "Overall scheme for CAR therapy in veterinary medicine." Cockey and Cynthia, 2023, used under [CC BY 4.0] (https://creativecommons.org/licenses/by/4.0/). Without modification.
- Cockey, James R., and Cynthia A. Leifer. "Racing CARs to veterinary immuno-oncology." Frontiers in Veterinary Science 10 (2023): 1130182.
- Wei, Jianshu, et al. "Target selection for CAR-T therapy." Journal of hematology & oncology 12 (2019): 1-9. Distributed under Open Access license CC BY 4.0, without modification.